Table 3.

Programmed Death Ligand 1 (PD-L1) positivity in metastatic sites in the Foundation Medicine (FM) database and in the IMpassion-130 data2

Sample type	FM total N(%)	FM N PD-L1+ (%)	IMpassion-130 total N(%)	IMpassion-130 N PD-L1+ (%)
Primary tumor	179 (52.6)	114 (63.7)	559 (62)	246 (44)
Metastatic lesion	161 (47.4)	68 (42.2)	342 (38)	123 (36)
Sites of metastases	N (% of metastatic samples)	N PD-L1+ (%)	IMpassion-130 N (% of metastatic samples)	IMpassion-130 N PD-L1+ (%)
Lung	16 (10.0)	11 (68.8)	54 (15.8)	23 (43)
Soft issues	23 (14.3)	15 (65.2)	36 (10.5)	11 (30)
Lymph nodes	45 (28.0)	23 (51.1)	108 (31.6)	55 (51)
Skin	21 (13.0)	5 (23.8)	18 (5.3)	9 (48)
Liver	23 (14.3)	4 (17.4)	45 (13.2)	6 (13)